Skip to main content
NIH funding notice PAR-17-263

Innovation for HIV Vaccine Discovery (R01)

Closed on August 1, 2019.

Posted
April 25, 2017
Close date
August 1, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,190,983 in first-year total cost, median $726,229.

Most frequent study sections

  1. HIV Immunopathogenesis and Vaccine Development Study Section[HIVD]2
  2. Special Emphasis Panel[ZRG1 AARR-P (03)]1

Most frequent institutions

  1. SCRIPPS RESEARCH INSTITUTE, THE2
  2. DUKE UNIVERSITY1
Competing awards under PAR-17-263 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Expediting elicitation of HIV-1 bnAbs with membrane Env vaccines1R01AI152523-01ZWICK, MICHAEL BSCRIPPS RESEARCH INSTITUTE, THE, CA$726,229HIVD
2019Supramolecular pediatric HIV vaccine design1R01AI145016-01COLLIER, JOEL HFOUDA AMOU OU, GENEVIEVE GINYDUKE UNIVERSITY, NC$793,206ZRG1
2019N-glycan baiting to target the highly effective HIV Env shield1R01AI145055-01WYATT, RICHARD THOMASSCRIPPS RESEARCH INSTITUTE, THE, CA$671,548HIVD

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.